pirfenidone has been researched along with Dyspnea in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (87.50) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Aguilar-Medina, S; Alva-Lopez, LF; Cazzola, M; Domínguez-Arellano, S; Escobar-Alvarado, JC; Falfán-Valencia, R; Matera, MG; Montiel-Lopez, F; Olaya-López, E; Pérez-Rubio, G; Poo, JL; Ramírez-Venegas, A; Sansores, RH; Zavaleta-Martínez, EO | 1 |
| Antoniou, K; Kamekis, A; Kokosi, M; Swigris, JJ; Symvoulakis, EK | 1 |
| Lederer, DJ; Martinez, FJ | 1 |
| Kishaba, T | 1 |
| Black, KE; Feneis, JF; Mark, EJ; Montesi, SB | 1 |
| Dobashi, K; Hachisu, Y; Hisada, T; Izuhara, K; Kaira, K; Koga, Y; Ohta, S; Ono, J; Tsurumaki, H; Yatomi, M | 1 |
| Albera, C; Behr, J; Chou, W; Costabel, U; Kirchgaessler, KU; Limb, SL; Morgenthien, E; Nathan, SD; Noble, PW; Stauffer, JL; Wuyts, WA | 1 |
| Albera, C; Gilberg, F; Glassberg, MK; Kirchgaessler, KU; Petzinger, U; Wijsenbeek, MS | 1 |
| Egan, J | 1 |
| Fukuda, Y; Goto, H; Hanibuchi, M; Morizumi, S; Nishioka, Y; Sato, S; Takahashi, M; Toyoda, Y | 1 |
| Bradford, WZ; Collard, HR; du Bois, RM; Ley, B; Vittinghoff, E; Weycker, D | 1 |
| Hanada, S; Kishi, K; Kurosaki, A; Miyamoto, A; Mochizuki, S; Morokawa, N; Murase, K; Ogawa, K; Takahashi, Y; Takaya, H; Takeyasu, M; Uruga, H | 1 |
| Albera, C; Costabel, U; Fagan, EA; Glassberg, MK; Gorina, E; Lancaster, L; Lederer, DJ; Nathan, SD; Spirig, D; Swigris, JJ | 1 |
| Hosein, K; Le, J; Mura, M | 1 |
| Celik, G; Ciledağ, A; Cirit Koçer, B; Kaya, A; Köktürk, N; Numanoğlu, N | 1 |
| Bajwah, S; Higginson, IJ; Koffman, J; Patel, AS; Peacock, JL; Riley, J; Ross, JR; Wells, AU | 1 |
4 review(s) available for pirfenidone and Dyspnea
| Article | Year |
|---|---|
Burden of idiopathic pulmonary fibrosis on patients' emotional well being and quality of life: a literature review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cough; Dyspnea; Fatigue; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Mental Health; Protein Kinase Inhibitors; Pyridones; Quality of Life | 2020 |
Idiopathic Pulmonary Fibrosis.
Topics: Diagnosis, Differential; Dyspnea; Enzyme Inhibitors; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Oxygen Inhalation Therapy; Prognosis; Pyridones; Risk Factors; Tomography, X-Ray Computed; Transforming Growth Factor beta | 2018 |
Evaluation and management of Idiopathic Pulmonary Fibrosis.
Topics: Biomarkers; Chronic Disease; Cough; Diagnosis, Differential; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Indoles; L-Lactate Dehydrogenase; Mucin-1; Pyridones; Respiratory Function Tests; Tomography, X-Ray Computed; Vital Capacity | 2019 |
Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Cough; Dyspnea; Exercise Test; Fibrosis; Glucocorticoids; Heroin; Humans; Immunologic Factors; Lung; Lung Diseases, Interstitial; Narcotics; Oxygen Inhalation Therapy; Piperazines; Prednisolone; Purines; Pyridones; Quality of Life; Sildenafil Citrate; Sulfones; Thalidomide; Tubulin Modulators | 2013 |
5 trial(s) available for pirfenidone and Dyspnea
| Article | Year |
|---|---|
Prolonged-release pirfenidone in patients with pulmonary fibrosis as a phenotype of post-acute sequelae of COVID-19 pneumonia. Safety and efficacy.
Topics: COVID-19; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Phenotype; Pneumonia; Pyridones | 2023 |
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Case-Control Studies; Dyspnea; Exercise Tolerance; Female; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Mortality; Placebos; Pulmonary Diffusing Capacity; Pyridones; Respiratory Function Tests; Treatment Outcome; Vital Capacity | 2019 |
Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Dyspnea; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Quality of Life; Severity of Illness Index; Sex Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vital Capacity | 2019 |
Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dyspnea; Female; Hospitalization; Humans; Idiopathic Pulmonary Fibrosis; Male; Models, Statistical; Proportional Hazards Models; Pyridones; Risk Assessment; Risk Factors; Surveys and Questionnaires; Vital Capacity | 2016 |
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Dyspnea; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Respiratory Function Tests; Surveys and Questionnaires; Tidal Volume; Treatment Outcome; Vital Capacity | 2016 |
7 other study(ies) available for pirfenidone and Dyspnea
| Article | Year |
|---|---|
Case 10-2019: A 69-Year-Old Man with Progressive Dyspnea.
Topics: Aged; Alveolitis, Extrinsic Allergic; Biopsy; Diagnosis, Differential; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Pyridones; Radiography, Thoracic; Sarcoidosis; Tomography, X-Ray Computed | 2019 |
Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion Molecules; Cough; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Male; Mucin-1; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Pyridones | 2019 |
Challenges in IPF diagnosis, current management and future perspectives: Patient case 1.
Topics: Aged; Dyspnea; Early Diagnosis; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Respiratory Function Tests; Risk Assessment; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
A Patient with Idiopathic Pleuroparenchymal Fibroelastosis Showing a Sustained Pulmonary Function due to Treatment with Pirfenidone.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; Pleural Diseases; Pyridones; Radiography, Thoracic; Respiratory Physiological Phenomena; Time Factors; Treatment Outcome; Vital Capacity; Weight Loss | 2016 |
Marked Improvement with Pirfenidone in a Patient with Idiopathic Pulmonary Fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cough; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Tomography, X-Ray Computed; Treatment Outcome; Vital Capacity | 2016 |
Assessing the Therapeutic Response to Pirfenidone in Idiopathic Pulmonary Fibrosis: Can We Do Better than with Forced Vital Capacity Alone?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Disease-Free Survival; Dyspnea; Female; Forced Expiratory Volume; Humans; Idiopathic Pulmonary Fibrosis; Longitudinal Studies; Male; Middle Aged; Pilot Projects; Prospective Studies; Pulmonary Diffusing Capacity; Pyridones; Treatment Outcome; Vital Capacity; Walk Test | 2017 |
A rare cause of interstitial lung disease: Hermansky-Pudlak syndrome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dyspnea; Fatal Outcome; Hermanski-Pudlak Syndrome; Humans; Male; Middle Aged; Pulmonary Fibrosis; Pyridones; Radiography, Thoracic; Respiratory Insufficiency; Tomography, X-Ray Computed | 2011 |